Aptevo Therapeutics
Market cap $1.6M 3.5M shares (10-Q, Nov 16, 2026) × $0.461 close Nov 17, 2026
Most recent annual filing: 2026-03-26
- Mipletamig Ph2 readoutyear-end 2026Mipletamig Ph2 readout, year-end 2026, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
ALG.APV-527
APVO603
- Undisclosed indication
APVO442
APVO711
- Undisclosed indication
APVO455
- Undisclosed indication
APVO451
APVO452
Technology platforms
ADAPTIR
ADAPTIR protein technology platform for rational design of monospecific and bispecific immunotherapeutic proteins targeting cancer; generates molecules that bind one or more targets with structural and functional advantages over monoclonal antibodies; used to develop clinical and preclinical oncology candidates
Targets: CD3, Nectin-4, PD-L1, CD40
ADAPTIR-FLEX
Proprietary flexible multispecific immunotherapy platform enabling adjustable construct design and addition of different therapeutic components; supports development of bispecific and trispecific candidates for solid tumors and hematologic malignancies, including Nectin-4 x PD-L1 backbone applications.
Targets: CD3, Nectin-4, PD-L1, CD40
Capital (as filed)
- Cash
- $8.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$5.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $8.3M cash, runway Q1 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-10-30 424B5 · At-the-market program up to $2.3M
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (6)
- 2026-11-17 UPDATE: Aptevo Therapeutics (APVO) - The Equity Cliff 🔒 Paid
- 2026-11-11 UPDATE: Aptevo Therapeutics (APVO) - Five Warrants for Every Share
- 2026-09-03 UPDATE: Aptevo Therapeutics (APVO) - Good Data, Wrong Week 🔒 Paid
- 2026-08-15 UPDATE: Aptevo Therapeutics (APVO) - They Just Locked Their Own Piggy Bank 🔒 Paid
- 2026-08-13 UPDATE: Aptevo Therapeutics (APVO) - The Warrant Treadmill Turns Again 🔒 Paid
- 2026-06-16 Aptevo Therapeutics (APVO) - Scientific Deep Dive for Mipletamig, ALG.APV-527, and the ADAPTIR Pipeline
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (6 calls)
Every verdict Biotech Distilled has published on Aptevo Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-16 Avoid Aptevo Therapeutics (APVO) - Scientific Deep Dive for Mipletamig, ALG.APV-527, and the ADAPTIR Pipeline Serial-dilution microcap with an unproven CRS-sparing CD123xCD3 in a class larger players are abandoning, an evaluable-vs-ITT efficacy pitch that cannot demonstrate additive benefit without a control arm, a stalled partner-encumbered second program, and an explicit going-concern qualification.
- 2026-08-13 Avoid UPDATE: Aptevo Therapeutics (APVO) - The Warrant Treadmill Turns Again $4.5M gross against ~$8.0M/quarter burn is a bridge to the next bridge, with new warrant overhang capping any RAINIER catalyst pop while the efficacy claim remains structurally unprovable.
- 2026-08-15 Avoid UPDATE: Aptevo Therapeutics (APVO) - They Just Locked Their Own Piggy Bank Management traded away 12 months of access to $66.8M in equity-line capacity for $4.5M gross, leaving the company with ~$9.8M cash, a restated going-concern, and a warrant plan struck 27% above the current price.
- 2026-09-03 Avoid UPDATE: Aptevo Therapeutics (APVO) - Good Data, Wrong Week A 79% CR/CRi in 14 TP53-mutant patients is the strongest clinical signal yet but cannot outrun 6.4 million registered resale shares against a 1.81 million share float, with warrants 58% out of the money and the capital plan effectively non-functional.
- 2026-11-11 Avoid UPDATE: Aptevo Therapeutics (APVO) - Five Warrants for Every Share $3.0M gross raise issues 13.9M new warrants at $1.08 while the stock closes at $0.76, starting the Nasdaq delisting clock with no cure period available and the equity lines still locked.
- 2026-11-17 Avoid UPDATE: Aptevo Therapeutics (APVO) - The Equity Cliff Three simultaneous Nasdaq listing tests, equity lines frozen until November 2027, ~$11M pro forma cash against ~$6.5M/quarter burn, and stockholders' equity near the $2.5M floor — the structure is deteriorating faster than the clinical signal is advancing.
- Avoid call · opened Jun 16, 2026 at $4.54 · -89.8% vs XBI +7.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Phase 1b dose optimization is targeted for completion by year-end 2026, with regulatory interaction planned for the first half of 2027.”
matched to Mipletamig · readout other
-
-
-
“With study completion targeted by year-end 2026 and regulatory interaction planned for the first half of 2027, Aptevo is moving closer to the next phase of clinical development, bringing mipletamig another step toward its potential role in frontline AML treatment.”
matched to Mipletamig · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (45)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseAptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q lands with $8.3M cash, 19.1M warrants outstanding against 3.5M shares, and a Nasdaq market-value reading of $2.9M — but 10 of 47 frontline AML patients have now bridged to curative transplant, and a priming-dose tweak has materially cut infusion reactions.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 12, 2026ReleaseAptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
- Nov 12, 20268-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1
- Nov 11, 2026ReleaseAptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds→ BD updateAptevo induced warrant holders to exercise at a repriced $1.08 strike — down 73% from the $4.03 strike set just three months ago — for $3.0M gross and issued 13.9M new warrants in return, while the stock cratered nearly 30% on the news.
- Nov 9, 2026ReleaseAptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
- Nov 9, 20268-KCurrent report: other events · EX-99.1
- Nov 5, 2026ReleaseAptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
- Nov 5, 20268-KCurrent report: other events · EX-99.1
- Nov 2, 20268-KCurrent report: other events
- Oct 30, 2026424B5Prospectus supplement (offering)
- Oct 26, 2026ReleaseAptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
- Oct 26, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → APVO pipeline
- Oct 23, 20268-KCurrent report: material agreement, holder rights modified
- Oct 14, 2026ReleaseAptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
- Oct 14, 20268-KCurrent report: other events · EX-99.1
- Sep 24, 2026ReleaseAptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
- Sep 24, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → APVO pipeline
- Sep 23, 20268-KCurrent report: shareholder vote
- Sep 3, 2026ReleaseAptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML→ BD updateSummary on the 8-K
- Sep 3, 20268-KCurrent report: other events · EX-99.1→ BD updateAptevo dropped a TP53 subgroup data release today — 79% CR/CRi in 14 evaluable patients vs. a published 41% ven/aza benchmark — on the exact same day the 6.4M-share warrant resale registration went effective, explaining the -41.8% stock collapse since August 14 and crystallizing the core tension: the most interesting clinical signal yet, arriving into the worst possible financing structure.BD extracted 1 program update from this document → APVO pipeline
- Sep 3, 2026424B4Prospectus (IPO / follow-on)→ BD updateSummary on the 8-K
- Aug 31, 2026DEF 14AProxy statement
- Aug 21, 2026S-1Registration statement
- Aug 21, 20268-KCurrent report: shareholder vote
- Aug 14, 2026ReleaseAptevo Provides 2Q26 Business Update and Reports Second Quarter Financial ResultsBD extracted 1 program update from this document → APVO pipeline
- Aug 14, 20268-KCurrent report: results of operations · EX-99.1
- Aug 14, 202610-QQuarterly report
- Aug 13, 2026ReleaseAptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
- Aug 13, 20268-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1
- Aug 12, 2026ReleaseAptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
- Jul 31, 2026DEF 14AProxy statement
- Jul 27, 2026ReleaseAptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
- Jul 27, 2026ReleaseAptevo Provides State of the Business Report and 2025 Financial Results
- Jul 27, 2026ReleaseAptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose SelectionBD extracted 1 program update from this document → APVO pipeline
- Jul 27, 20268-KCurrent report: other events · EX-99.1
- Jun 30, 20268-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- May 27, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1
- May 13, 20268-KCurrent report: results of operations · EX-99.1
- May 13, 202610-QQuarterly report
- May 6, 20268-KCurrent report: other events · EX-99.1
- Mar 26, 20268-KCurrent report: results of operations · EX-99.1
- Mar 26, 202610-KAnnual report
- Mar 11, 20268-KCurrent report: other events · EX-99.1
13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 12, 2026SCHEDULE 13G/A13G amendment
- Nov 12, 2026PRE 14APRE 14A
- Sep 25, 2026S-8Employee plan registration
- Sep 2, 2026EFFECTRegistration effective
- Aug 31, 2026CORRESPCORRESP
- Aug 27, 2026UPLOADUPLOAD
- Aug 26, 2026DForm D (exempt offering)
- Aug 21, 2026PRE 14APRE 14A
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 31, 2026ARSAnnual report to shareholders
- Jul 24, 2026S-8Employee plan registration
- Jun 22, 2026SCHEDULE 13GPassive >5% holder (13G)